$18.96
−12.02%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$22.10
From 52W high−80.25%
Volume497227.00
Market cap$187.02M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$22.10
From 52W high
−80.25%
Volume
497227.00
Market cap
$187.02M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.4x
P/E (TTM)
—
RSI (14)
19.8
MomentumView details →
1D Return
−12.02%
YTD Return
−75.46%
SummaryUpdated Jun 1, 2026
Bright Minds Biosciences Inc. (NASDAQ:DRUG) is a pre-clinical stage biotechnology company founded in 2019 and headquartered in Vancouver, Canada. The company went public in March 2021 and focuses on developing novel serotonin-based medicines for patients with severe neurological and psychiatric conditions. As a pre-clinical biotech firm, Bright Minds has not yet generated revenue from product sales and remains in the research and development phase of bringing potential treatments to market.
Similar companies
Latest newsMore news →
The FDA placed Bright Minds Biosciences’ IND for BMB-101 in developmental and epileptic encephalopathies and related Protocol BMB-101-105 on partial clinical hold.2d agoVistagen Therapeutics appointed Douglas J. Williamson, M.D. as a director, effective July 29, 2026, with stock option compensation and eligibility for the Director Compensation Plan.97d ago